Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DNM1 | Q05193 | 2/20 | 0.49 |
| ▸ | FAAH | O00519 | 4/20 | 0.47 |
| ▸ | CASP2 | P42575 | 1/20 | 0.47 |
| ▸ | CNR1 | P21554 | 1/20 | 0.45 |
| ▸ | NAAA | Q02083 | 1/20 | 0.44 |
| ▸ | ICMT | O60725 | 2/20 | 0.44 |
| ▸ | ALB | P02768 | 2/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.39 |
| ▸ | KDM5A | P29375 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL889199 | 0.94 | DNM1 (0.51) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL17615499 | 0.93 | NAAA (0.47) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL19546069 | 0.91 | CASP2 (0.52) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL889136 | 0.90 | MCL1 (0.48) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL19681637 | 0.89 | DNM1 (0.56) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL19726631 | 0.88 | DNM1 (0.49) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL889148 | 0.88 | PAOX (0.45) | DNM1FAAHCASP2CNR1NAAA | |
| SCHEMBL12792384 | 0.87 | CASP2 (0.67) | DNM1FAAHCASP2NAAAICMT | |
| SCHEMBL12791957 | 0.87 | CASP2 (0.67) | DNM1FAAHCASP2NAAAICMT | |
| SCHEMBL12791707 | 0.87 | CASP2 (0.67) | DNM1FAAHCASP2NAAAICMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | THE BROAD INSTITUTE, INC. (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240018552-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2024-01-18 | — | — | US | disclosed |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | UNIV TUFTS (US) | 2016-03-24 | — | — | US | disclosed |
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2012-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120009222-A1 | MODULATION OF THE IMMUNE RESPONSE | FCGRT, MYD88, C3AR1 | DNM1 4279/4885FAAH 858/4885CASP2 2840/4885 |
| US-12018080-B2 | Methods and compositions for treating cancer by targeting the CLEC2D-KLRB1 pathway | KLRK1, CD47, FCGR3B | DNM1 3022/4885FAAH 4542/4885CASP2 2004/4885 |
| US-20240018552-A1 | NOVEL CRISPR ENZYMES AND SYSTEMS | CPSF1, CPSF6, CPN1 | DNM1 3631/4885FAAH 3839/4885CASP2 2457/4885 |
| US-20160082126-A1 | NANOCOMPLEXES FOR DELIVERY OF SAPORIN | SARNP, SAP30BP, SCP2 | DNM1 3713/4885FAAH 3722/4885CASP2 1350/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.